CNO

CNO Financial Group, Inc. - Q1 2026 Filing Summary

Business Context and Reporting Period

This summary covers the unaudited Form 10-Q for CNO Financial Group, Inc. for the quarterly period ended March 31, 2026. CNO is a holding company for a group of insurance companies focusing on health insurance, annuities, and individual life insurance for middle-income pre-retiree and retired Americans. The company operates through Annuity, Health, and Life product lines, supported by Investment and Fee Income segments. In November 2025, the company announced an exit from its fee services business within the Worksite Division, which is expected to be substantially completed by June 30, 2026.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability: Net income increased 75% to $37.7 million, driven by higher operating earnings and lower non-operating losses compared to Q1 2025. Net Operating Income rose 25% to $101.3 million.
• Revenue Growth: Total revenues increased 2.5% primarily due to growth in insurance policy income and net investment income. Health segment margin increased to $132.6 million (from $126.2 million) due to lower morbidity and business growth.
• Investment Performance: The company reported total investment losses of $22.7 million (vs. $6.8 million in Q1 2025), including $15.2 million in net realized losses and a $9.4 million increase in the allowance for credit losses. Gross unrealized losses on fixed maturities totaled $2,273.2 million.
• Equity Impact: Shareholders' equity decreased by $139.8 million to $2,498.4 million, largely due to a $102.6 million net of tax Other Comprehensive Loss (OCL) driven by unrealized investment losses of $324.6 million before tax.
• Expense Management: The expense ratio improved to 18.9% from 19.9% in the prior year, aided by timing of expenses and lower advertising costs in the Life segment.

Guidance, Outlook, and Risks

• 2026 Guidance: Management reaffirmed guidance for operating earnings per diluted share in the range of $4.25 to $4.45. The expected expense ratio is 18.8% to 19.2%, and the effective tax rate is expected to be approximately 22.5%.
• Capital Targets: The company targets a consolidated Risk-Based Capital (RBC) ratio of 360% to 390% (actual was 375% at March 31, 2026) and a debt-to-total capital ratio of 25% to 28%.
• Dividend: The quarterly common stock dividend was increased to $0.18 per share in May 2026 (from $0.17).
• Strategic Initiatives: The company is executing "TechMod," a three-year technology modernization project expected to cost approximately $170 million total, with $76 million expected in 2026. These costs are excluded from operating earnings.
• Risks: Key risks include interest rate volatility impacting investment values and policyholder behavior, the outcome of pending litigation (including the Burnett v. Conseco class action), and the ability to obtain rate increases for health products. The company also faces potential Section 382 limitations on Net Operating Losses if an ownership change occurs.

Investor Verification Checklist

• Investment Portfolio Quality: Verify the composition of the $2,273.2 million in gross unrealized losses and the $43.9 million allowance for credit losses to assess potential future impairments.
• Health Segment Margins: Monitor the sustainability of the improved Health margin (31% of policy income) given the reliance on lower morbidity and the impact of pending rate increases.
• Fee Services Exit: Confirm the timeline and financial impact of exiting the Worksite Division fee services business, which is expected to reduce annual fee revenue by ~$30 million but increase pre-tax income by ~$20 million.
• Technology Costs: Track the actual spend on the TechMod initiative against the $76 million 2026 budget to ensure it remains within the non-operating exclusion criteria.
• Liquidity and Debt: Review the $2.7 billion in FHLB borrowings and the $1.3 billion in direct corporate obligations to ensure compliance with debt covenants and liquidity targets.